BMRN (STOCKS)
BioMarin Pharmaceuticals Inc
$68.530000
-1.710000 (-2.43%)
Prev close: $70.240000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alexander Hardy
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $15,527.34M
- Employees
- 3,040
- P/E (TTM)
- 189.38
- P/B (TTM)
- 2.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
16
Buy
7
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.73 | $0.70 | +0.0284 | +4.05% |
|
Mar 2026 (Q1)
|
$0.54 | $0.77 | -0.2256 | -29.47% |
|
Dec 2025 (Q4)
|
$-0.24 | $0.64 | -0.8770 | -137.68% |
|
Sep 2025 (Q3)
|
$-0.16 | $0.38 | -0.5393 | -142.18% |
Financial Statements
| Revenues | $3.41B |
| Benefits Costs and Expenses | $3.26B |
| Cost Of Revenue | $813.59M |
| Costs And Expenses | $3.26B |
| Gross Profit | $2.59B |
| Operating Expenses | $2.44B |
| Selling, General, and Administrative Expenses | $1.37B |
| Research and Development | $987.64M |
| Other Operating Expenses | $87.67M |
| Operating Income/Loss | $149.26M |
| Income/Loss From Continuing Operations After Tax | $72.97M |
| Income/Loss From Continuing Operations Before Tax | $149.11M |
| Income Tax Expense/Benefit | $76.14M |
| Income Tax Expense/Benefit, Deferred | -$10.77M |
| Net Income/Loss | $72.97M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $72.97M |
| Net Income/Loss Available To Common Stockholders, Basic | $72.97M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.38 |
| Diluted Earnings Per Share | $0.37 |
| Basic Average Shares | 385,139,000 |
| Diluted Average Shares | 386,680,000 |
| Assets | $11.72B |
| Current Assets | $3.97B |
| Inventory | $1.78B |
| Other Current Assets | $2.19B |
| Noncurrent Assets | $7.75B |
| Fixed Assets | $989.99M |
| Intangible Assets | $4.88B |
| Other Non-current Assets | $1.88B |
| Liabilities | $5.40B |
| Current Liabilities | $1.66B |
| Wages | $220.51M |
| Other Current Liabilities | $1.44B |
| Noncurrent Liabilities | $3.74B |
| Long-term Debt | $4.19B |
| Equity | $6.32B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.32B |
| Liabilities And Equity | $11.72B |
| Net Cash Flow From Operating Activities | $857.09M |
| Net Cash Flow From Operating Activities, Continuing | $857.09M |
| Net Cash Flow From Investing Activities | -$4.75B |
| Net Cash Flow From Investing Activities, Continuing | -$4.75B |
| Net Cash Flow From Financing Activities | $3.55B |
| Net Cash Flow From Financing Activities, Continuing | $3.55B |
| Net Cash Flow | -$340.14M |
| Net Cash Flow, Continuing | -$340.14M |
| Comprehensive Income/Loss | $108.75M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $108.75M |
| Other Comprehensive Income/Loss | $108.75M |
| Other Comprehensive Income/Loss Attributable To Parent | $35.78M |